Showing results (211-220 of 220) with videos related to
Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 220 results.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLBoglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.Blood|July 21, 2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R Mato, Lindsey E Roeker, Nicole Lamanna, et al.Pageof 22